The papers stay within reach of the story.
These are the sources we link to in Peptide Studies. Each note says what we used it for. A trial, a review and prescribing information do different jobs, even when they discuss the same compound.
The human weight trial and the rat tendon experiment
The opening page moves from people to rats. These sources help keep that change clear, with separate safety and human-evidence context.
The semaglutide weight trial
Wilding and colleagues, 2021. Adults without diabetes received semaglutide or placebo. This is where the opening weight comparison comes from.
The semaglutide safety review
Smits and Van Raalte, 2021. We use this review for digestive effects and gallbladder risk. It adds safety context to the account.
BPC-157 and a cut rat Achilles tendon
Staresinic and colleagues, 2003. This is the tendon-healing experiment. It also reports the separate work on tendon cells outside the rats.
The later review of BPC-157 repair research
McGuire and colleagues, 2025. We use this review to explain the very limited human evidence. It identifies the need for larger, rigorous trials.
The tirzepatide and retatrutide leaves
The weight trials provide comparisons within each study. The other sources explain targets, safety and approval; they aren't extra weight-loss trials.
The tirzepatide obesity trial
Jastreboff and colleagues, 2022. The source for weight changes over 72 weeks. It also reports the digestive side effects.
Tirzepatide prescribing information
The source for warnings about severe digestive problems and kidney injury linked to fluid loss. It also covers slow stomach emptying.
The early retatrutide obesity trial
Jastreboff and colleagues, 2023. This 48-week trial supplies the weight finding. It also reports digestive effects and increased heart rate.
Retatrutide's three receptor targets
Research on how retatrutide interacts with three hormone receptors. We use it to explain the targets, rather than predict a personal benefit.
A review of retatrutide's early research
Katsi and colleagues, 2025. This brings early findings together. We use it for context on the weight results and side effects.
FDA information on unapproved GLP-1 drugs
The source for retatrutide's lack of FDA approval. An encouraging research result doesn't change that distinction.
The tesamorelin and PT-141 leaves
These papers measure different things: fat around the organs, desire and distress. The prescribing information keeps approved uses and safety warnings close by.
The tesamorelin trial in adults with HIV
Falutz and colleagues, 2007. The source for the visceral-fat result over 26 weeks. We use the paper's percentages in our account.
Tesamorelin prescribing information
The source for the approved use and weight-neutral description. It also supplies the blood-sugar, growth-signal and active-cancer cautions.
The longer tesamorelin follow-up
Falutz and colleagues, 2008. This supports the note about visceral fat returning after treatment stopped. It is separate from the first trial report.
The two bremelanotide desire trials
Kingsberg and colleagues, 2019. The source for changes in desire and related distress over 24 weeks. It also reports common side effects.
Bremelanotide prescribing information
The source for the approved population and temporary blood-pressure rise. It also explains the limits for people with certain cardiovascular conditions.
A link supports the statement beside it. It doesn't settle every question about that compound. If a claim seems bigger than the account, returning to the original paper is a good way to see where the difference begins.